This is a fascinating podcast episode from Dr. Lipid himself on desmosterol.  What is it?  How do we measure it?  Why should we care?

On 'This Week in Pharmacy' we're talking about the "Fully Powered Event" with Dr. Christina Fontana, we jump into TWIRx News with Andy Crawford from Keysource, preparing for the NASP 2025 in Denver & welcome the Rated Rx Podcast to the PPN!

In this episode, we sit down with the President of the American Medical Association to discuss PBM reform and its impact on patients, physicians, and the future of healthcare. From drug pricing transparency to ensuring access to needed medications, this conversation explores why PBM reform is at the center of today’s healthcare policy debates.

In this final part of this three part series we bring you exclusive interviews from the Outcomes booth, recorded on the show floor at ThoughtSpot 2025.

Our guests are:

This episode is sponsored by Outcomes.

Join our co-hosts Todd Eury and Greg Reybold in this exclusive interview with Conor Sheehey, who most recently served as senior health policy advisor to U.S. Senate Finance Committee Chair Mike Crapo (R-ID). In this role, he advised the Committee on a range of health care policy issues, including prescription drug pricing, telehealth, AI, provider coverage and reimbursement, fraud and abuse, medical devices, and Medicare Parts B and D. Sheehey led several bipartisan legislative efforts, including the development of comprehensive PBM reforms and bipartisan proposals on clinician payment reform and drug shortages.

Psilocybin has demonstrated a long track record of safety and efficacy in a variety of conditions including depression, anxiety, addiction, trauma, and cognitive decline. Although to date, this natural substance remains classified as a Schedule 1 drug, there are protected use scenarios including sincere spiritual use. The Religious Freedom Restoration (RFRA) act lies at the foundation of Setas Seminary's protected use of psilocybin sacrament.

Welcome (back) to the Opioidology podcast series! Next up to bat, ‘Opioid Selection”.